Embedded Files
The Challenge
in Neurological Trials
The Challenge
in Neurological Trials
Clinical trials in neurological disorders are slow, costly, and high-risk. Patient populations are diverse, and traditional endpoints can take years to show a meaningful signal. This uncertainty can obscure a new therapy's true effect and delay critical breakthroughs.
Our Solution:
The Prognostic Platform
Our Solution:
The Prognostic Platform
We've built a multimodal prognostic platform to solve this. By analyzing complex, real-world data, we provide a new tool for drug developers: a validated forecast of an individual patient's disease progression.
We've built a multimodal prognostic platform to solve this. By analyzing complex, real-world data, we provide a new tool for drug developers: a validated forecast of an individual patient's disease progression.
Introducing the AD-PxTM Engine
The AD-PxTM prognostic engine, provides a new window into Alzheimer's disease.
The AD-PxTM prognostic engine, provides a new window into Alzheimer's disease.
It gives researchers the ability to see a patient's likely future, today.
It gives researchers the ability to see a patient's likely future, today.
Boost Power Without Adding Participants
Boost Power Without Adding Participants
Our prognostic tools give you two ways to boost statistical power from the start:
Smarter Patient Selection: Use our forecasts to identify and select patients most likely to progress. This enriches your trial population to see a clearer signal.
Covariate Adjustment: Use our forecasts as a powerful covariate in your analysis to account for variance.
Reduce Sample Size, Maintain Power
Reduce Sample Size, Maintain Power
Both methods help you boost statistical power, or alternatively, reduce sample sizes.
Increase Inclusivity Without Compromising Power
Increase Inclusivity Without Compromising Power
Enroll a more diverse, real-world patient population. Our tools help you manage and account for higher variability, allowing for more inclusive trial designs without sacrificing the power to see a signal.
To learn more, visit our Publications page!
Yoshua Bengio, Ph.D.
Yoshua Bengio, Ph.D.
Full Professor at Université de Montréal,
Founder and Scientific Director of Mila,
Scientific Director of IVADO
Serge Gauthier, M.D.
Serge Gauthier, M.D.
Full Professor at McGill University,
Director of the Alzheimer Disease and Related Disorders Research Unit, Douglas Research Centre
Richard H. Stark, M.S.
Richard H. Stark, M.S.
Physicist, Entrepreneur & Investor Former Executive at Varian, ViewRay and Elekta
Betsabeh Madani Hermann, M.B.A.
Betsabeh Madani Hermann, M.B.A.
Healthcare executive & investor,
Global Head of Research
Our Partners
Our Partners
We have partnered with some of the most innovative actors in the business. A resident of JLABS Johnson & Johnson
We have partnered with some of the most innovative actors in the business. A resident of JLABS Johnson & Johnson
Page updated
Report abuse